Biomarkeri si agenti de chimiopreventie in ... - Prezentare
Biomarkeri si agenti de chimiopreventie in ... - Prezentare
Biomarkeri si agenti de chimiopreventie in ... - Prezentare
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Nr proiect: 62-078/2008<br />
Titlu proiect:<br />
<strong>Biomarkeri</strong> <strong>si</strong> <strong>agenti</strong> <strong>de</strong> <strong>chimiopreventie</strong> <strong>in</strong><br />
limfoproliferarile cronice<br />
Director Proiect:<br />
Dr.Viviana Roman, CS II
Parteneri <strong>in</strong> consortiu:<br />
CO: Institutul <strong>de</strong> Virusologie, Centrul <strong>de</strong> Imunologie, Bucuresti<br />
P1: Spitalul Univer<strong>si</strong>tar Bucuresti-Cl<strong>in</strong>ica <strong>de</strong> Hematologie<br />
P2: Univer<strong>si</strong>tatea <strong>de</strong> Medic<strong>in</strong>a <strong>si</strong> Farmacie Bucuresti-Cl<strong>in</strong>ica <strong>de</strong><br />
hematologie<br />
P3: Univer<strong>si</strong>tatea Bucuresti, Baza <strong>de</strong> cercetare cu utilizatori<br />
multiplii-Biologie Moleculara<br />
Buget: 2.000.000 lei<br />
Adresa web proiect: www.vivianaroman.27.ro (1076 accesari)
Obiectiv/rezultat f<strong>in</strong>al proiect:<br />
1) Realizarea unei cercetari complexe <strong>in</strong>terdiscipl<strong>in</strong>are <strong>in</strong> domenii <strong>in</strong>terconectate <strong>de</strong> hematologie, biochimie,<br />
biologie referitoare la efectul unor <strong>agenti</strong> <strong>de</strong> <strong>chimiopreventie</strong> <strong>in</strong> limfoproliferarile cronice pr<strong>in</strong> meto<strong>de</strong><br />
mo<strong>de</strong>rne <strong>de</strong> biologie celulara <strong>si</strong> moleculara sau <strong>de</strong> genetica<br />
2) Acumularea <strong>de</strong> noi cunosti<strong>in</strong>te priv<strong>in</strong>d actiunea <strong>agenti</strong>lor <strong>de</strong> <strong>chimiopreventie</strong> <strong>si</strong> o mai buna <strong>in</strong>telegere a<br />
mecanismelor bazale ale biomarkerilor<br />
3) Promovarea rezultatele relevante <strong>si</strong> <strong>in</strong> alte tipuri <strong>de</strong> cancer pentru a obt<strong>in</strong>e strategii pentru viitoarele trialuri<br />
cl<strong>in</strong>ice, avand ca scop o <strong>chimiopreventie</strong> <strong>si</strong>gura <strong>si</strong> eficienta<br />
Elemente <strong>de</strong> noutate ale proiectului; orig<strong>in</strong>alitate<br />
1) O noua perspectiva pentru cl<strong>in</strong>icieni pr<strong>in</strong> <strong>in</strong>troducerea acestor biomarkeri <strong>in</strong> practica cl<strong>in</strong>ica pentru<br />
imbunatatirea diagnosticului <strong>si</strong> a starii <strong>de</strong> sanatate a populatiei-<br />
2) Pr<strong>in</strong> selectia biomarkerilor <strong>si</strong> a <strong>agenti</strong>lor <strong>de</strong> <strong>chimiopreventie</strong>, mo<strong>de</strong>lul experimental creat este unic<br />
3) Pentru prima data <strong>in</strong> tara Dr. H. Bumbea a realizat <strong>de</strong>term<strong>in</strong>area expre<strong>si</strong>ei ZAP-70 (conform cu<br />
protocolul standardizat ERIC- dr. F. Cymbalista, Paris, Fr.) <strong>si</strong> corelatia cu alti biomarkeri (CD38, CD23)<br />
pentru un diagnostic cat mai precis <strong>si</strong> un tratament ulterior cat mai a<strong>de</strong>cvat.<br />
4) Pentru prima data <strong>in</strong> tara Dr. V.Roman a <strong>de</strong>term<strong>in</strong>at expre<strong>si</strong>a unor biomarkeri specifici LLC-B <strong>si</strong> va<br />
<strong>de</strong>term<strong>in</strong>a mutatiile somatice <strong>in</strong> IgVh (conform protocol standardizat ERIC, Dr. K. Stamatopoulos,<br />
Thessaloniki, Gr.)<br />
5) Crearea Grupului <strong>de</strong> diagnostic <strong>in</strong> limfoproliferarile cronice <strong>si</strong> participarea atat <strong>in</strong> Reteaua <strong>de</strong> Leucemie<br />
Europeana (ELN) cat <strong>si</strong> <strong>in</strong> Grupul <strong>de</strong> lucru (ELN-WP 7) pentru studiul leucemiei cronice limfocitare (ERIC)
Beneficiarii rezultatelor; potential <strong>de</strong> aplicare <strong>in</strong> economie<br />
Impactul economic-f<strong>in</strong>anciar: pr<strong>in</strong> prisma costurilor sociale, facilitarea unui diagnostic precoce, o mai buna<br />
schema terapeutica, cu ameliorarea prognosticului <strong>si</strong> a sperantei <strong>de</strong> viata chiar pentru pacienti cu prognostic nu<br />
foarte favorabil este un castig avand <strong>in</strong> ve<strong>de</strong>re reducerea costurilor <strong>de</strong> spitalizare <strong>si</strong> implicit a medicamentelor<br />
utilizate. Toate acestea fac ca noile meto<strong>de</strong> <strong>de</strong> diagnostic <strong>si</strong> tratament sa fie cost-eficiente.<br />
Impactul tehnic: rezultatele proiectului ar putea contribui la cresterea performantelor laboratoarelor <strong>de</strong><br />
biologie moleculara (pr<strong>in</strong> disem<strong>in</strong>area unor tehnici noi), ar putea oferi oportunitati pentru <strong>in</strong>vatamant <strong>si</strong><br />
perfectionare, crearea <strong>de</strong> noi locuri <strong>de</strong> munca pentru absolventi <strong>de</strong> facultate, la cresterea performantelor<br />
cercetarii românesti <strong>si</strong> la <strong>in</strong>tegrarea acesteia în cercetarea europeana.<br />
Impactul social: crearea unor noi locuri <strong>de</strong> munca pentru t<strong>in</strong>eri cercetatori; pr<strong>in</strong> asociatii ale pacientilor<br />
bolnavi <strong>de</strong> cancer sau <strong>in</strong>stitutii <strong>de</strong> <strong>in</strong>teres public, rezultatele d<strong>in</strong> prezentul proiect ar putea conduce la noi terapii,<br />
imbunatatirea eficientei celor <strong>in</strong> curs, reducerea <strong>in</strong> mai mare masura a efectelor secundare, conditii mai bune <strong>de</strong><br />
munca <strong>si</strong> viata a pacientilor afectati <strong>de</strong> aceste maladii, cresterea sperantei <strong>si</strong> calitatii vietii pacientilor cu<br />
limfoproliferari maligne.<br />
Impactul educational: colectivele <strong>de</strong> cercetatori implicate în acest proiect vor contribui <strong>in</strong> cadrul unor <strong>de</strong><br />
mese rotun<strong>de</strong>, <strong>si</strong>mpozioane, ateliere <strong>de</strong> lucru la disem<strong>in</strong>area rezultatelor pe etape ale acestui proiect <strong>si</strong> <strong>in</strong>clu<strong>si</strong>v<br />
la disem<strong>in</strong>area <strong>de</strong> noi tehnici <strong>de</strong> laborator, atât în Bucuresti, cât <strong>si</strong> în alte centre univer<strong>si</strong>tare cu preocupari în<br />
acest domeniu.
Stadiul <strong>de</strong> realizare al proiectului <strong>in</strong> 2010 –conform Act Aditional 2010<br />
Etapa 1<br />
Elaborarea mo<strong>de</strong>lului experimental <strong>in</strong> ve<strong>de</strong>rea optimizarilor meto<strong>de</strong>lor <strong>de</strong> lucru (26.02.2009)<br />
Etapa 2<br />
Expre<strong>si</strong>a unor biomarkeri <strong>in</strong>a<strong>in</strong>te <strong>de</strong> tratarea cu AC (15.12.2009)<br />
Etapa 3<br />
Studiul modularii expre<strong>si</strong>ei biomarkerilor luati <strong>in</strong> studiu <strong>in</strong>a<strong>in</strong>te <strong>si</strong> dupa tratarea cu AC (10.12.2010)<br />
Buget <strong>de</strong> stat:<br />
An <strong>de</strong>rulare Valoarea alocată <strong>de</strong> la bugetul <strong>de</strong> stat Cof<strong>in</strong>anţare<br />
proiect Lei Credite <strong>de</strong> angajament<br />
2009 110.895 61.206 0<br />
2010 - 264.877 0<br />
2011 1.563.022 - 0<br />
Total 1.673.917 326.083 0
Activitati efectuate:<br />
1) Stabilirea criteriilor <strong>de</strong> alcatuire a lotului <strong>de</strong> studiu d<strong>in</strong> pacientii diagnosticati cu LC<br />
2) Colectarea probelor biologice;alcatuirea lotului <strong>de</strong> pacienti; largirea lotului <strong>de</strong> pacienti;<br />
3) Stabilirea diagnosticului <strong>si</strong> standardizarea acestuia pr<strong>in</strong> examen cl<strong>in</strong>ic, <strong>de</strong> laborator <strong>si</strong> imagistic<br />
4) Determ<strong>in</strong>area viabilitatii <strong>in</strong> functie <strong>de</strong> conditiile experimentale <strong>de</strong> studiu<br />
5) Determ<strong>in</strong>area nivelului <strong>de</strong> expre<strong>si</strong>e a unor markeri implicati <strong>in</strong> diagnostic<br />
6) Determ<strong>in</strong>area procentului <strong>de</strong> celule apoptotice la nivel membranar dupa tratarea cu AC<br />
7) Evi<strong>de</strong>ntierea fenomenului <strong>de</strong> apoptoza pr<strong>in</strong> studiul potentialului transmembranar mitocondrial<br />
8) Determ<strong>in</strong>area nivelului <strong>de</strong> expre<strong>si</strong>e <strong>si</strong> a ARNm corespunzator pentru ZAP-70, CD23 <strong>in</strong>ante <strong>de</strong> tratarea cu<br />
AC-partial<br />
9) Determ<strong>in</strong>area nivelului <strong>de</strong> expre<strong>si</strong>e <strong>si</strong> a ARN m corespunzator pentru ZAP-70, CD23 dupa tratarea cu ACpartial<br />
10) Determ<strong>in</strong>area nivelului <strong>de</strong> expre<strong>si</strong>e <strong>si</strong> a ARNm corespunzator pentru prote<strong>in</strong>ele pro/antiapoptotice <strong>in</strong>ante<br />
<strong>de</strong> tratarea cu AC-partial<br />
11) Determ<strong>in</strong>area nivelului <strong>de</strong> expre<strong>si</strong>e <strong>si</strong> a ARNm corespunzator pentru prote<strong>in</strong>ele pro/antiapoptotice dupa<br />
tratarea cu AC-partial<br />
12) Determ<strong>in</strong>area ARNm corespunzator pentru caspaza 3 <strong>si</strong> 8 <strong>in</strong>ante <strong>si</strong> dupa tratarea cu AC<br />
13) Determ<strong>in</strong>area expre<strong>si</strong>ei <strong>si</strong> a ARNm corespunzator pentru Hsp 70 <strong>si</strong> Hsp 90 <strong>in</strong>ante <strong>si</strong> dupa tratarea cu AC<br />
14) Corelatii <strong>in</strong>tre nivelul <strong>de</strong> expre<strong>si</strong>e al diferitilor markerilor luati <strong>in</strong> studiu. Prelucrarea statistica a datelor<br />
stocate <strong>si</strong> arhivate - partial<br />
15) Disem<strong>in</strong>area rezultatelor<br />
Achizitii efectuate: la <strong>in</strong>dicatiile CNMP, nu s-au efectuat
Modul <strong>de</strong> implicare a t<strong>in</strong>erilor cercetatori:<br />
Avand <strong>in</strong> ve<strong>de</strong>re numarul <strong>de</strong> t<strong>in</strong>eri sub 30 ani (CO-4, P1-2, P2-3, P3-4) implicati <strong>in</strong> acest proiect, ne dorim ca pr<strong>in</strong> acest<br />
proiect sa ajutam la sust<strong>in</strong>erea specializarii resurselor umane pr<strong>in</strong> participarea la elaborarea unor <strong>de</strong> teze <strong>de</strong> licenta,<br />
teze <strong>de</strong> dizertatie <strong>si</strong> teze <strong>de</strong> doctorat. Toate aceste ne vor duce cu <strong>si</strong>guranta la o mai buna colaborare <strong>in</strong>tre spitale,<br />
centre <strong>de</strong> cercetare <strong>si</strong> univer<strong>si</strong>tati.<br />
Diplome <strong>si</strong> mentiuni (UMF CAROL DAVILA)<br />
PROSPECTIVE ANALYSIS OF PATIENTS WITH HEPATITIS VIRUSES AND CHRONIC LYMPHOPROLIFERATIVE<br />
DISORDERS<br />
Ion IM,Delcea C, NistorSI, Iliescu MC, Ciufu C, Vladareanu AM, Arama V, YES Meet<strong>in</strong>g Porto, 26 september 2010,<br />
Portugal(prezentare orala), Premiu-Honorable Mention la se<strong>si</strong>unea Oncology and Molecular Biology<br />
Lucrari <strong>de</strong> diploma elaborate referitor la tema proiectului:<br />
Implicatiile virusurilor hepatitice <strong>in</strong> etiopatogenia limfoprolierarilor cornice <strong>si</strong> acute<br />
-Lucrare aflata <strong>in</strong> curs <strong>de</strong> <strong>de</strong>sfasurare- stu<strong>de</strong>nta Ion Ioana Maria sub coordonarea sti<strong>in</strong>tifica Prof. Univ. Dr. Ana-Maria<br />
Vladareanu <strong>si</strong> sub <strong>in</strong>drumarea A<strong>si</strong>st. Univ.Dr.Crist<strong>in</strong>a Ciufu<br />
Fenomene autoimmune <strong>in</strong> leucemia limfocitara cronica-corelatii cl<strong>in</strong>ic-evolutive<br />
-Lucrare realizata <strong>de</strong> stu<strong>de</strong>nta Florica Idor, sub coordonarea sti<strong>in</strong>tifica a Prof. Univ. Dr. Ana-Maria Vladareanu <strong>si</strong> Sef lucr.<br />
Dr Horia Bumbea, Lucrarea a fost sust<strong>in</strong>uta <strong>in</strong> cadrul Se<strong>si</strong>unii Examene <strong>de</strong> Diploma UMF Carol Davila la Spitalul<br />
Colent<strong>in</strong>a-27 septembrie 2010-notata cu nota 10.<br />
Teze <strong>de</strong> doctorat:<br />
1) Evaluarea parametrilor morfologici <strong>si</strong> imunofenotipici <strong>in</strong> diagnosticul limfoproliferarilor cronice <strong>de</strong> l<strong>in</strong>ie B, cu<br />
<strong>de</strong>scarcare periferica- implicatii prognostice ; doctorand Ana-Maria Iova, MD, Conducator <strong>de</strong> doctorat: Prof.Dr. Ana-<br />
Maria Vladareanu<br />
2)Evaluarea markerilor bioumorali <strong>si</strong> genetici cu valoare prognostica <strong>in</strong> LLC –implicatii cl<strong>in</strong>ice, Dr. Elena<br />
Andrus, sub coordonarea sti<strong>in</strong>tifica a Prof. Dr. Ana-Maria Vladareanu;<br />
3) Implicarea unor substante biologic active <strong>in</strong> modularea procesului apoptotic <strong>in</strong> cancer; doctorand Dan<br />
Hotnog, Conducator <strong>de</strong> doctorat: Dr. Rodica Repanovici, Coordonator sti<strong>in</strong>tific: Dr. Viviana Roman<br />
A existat <strong>si</strong> o a patra teza <strong>de</strong> doctorat dar d<strong>in</strong> motive f<strong>in</strong>anciare a fost abandonata
Indicatorii <strong>de</strong> rezultat realizati <strong>in</strong> cadrul proiectului<br />
1) Studii <strong>de</strong> nece<strong>si</strong>tate publica <strong>de</strong> <strong>in</strong>teres local care au cupr<strong>in</strong>s: stabilirea criteriilor <strong>de</strong> alcatuire a lotului <strong>de</strong><br />
studiu d<strong>in</strong> pacientii diagnosticati cu LC ; colectarea probelor <strong>si</strong> stabilirea diagnosticului <strong>si</strong> standardizarea<br />
acestuia pr<strong>in</strong> examen cl<strong>in</strong>ic, <strong>de</strong> laborator <strong>si</strong> imagistic; corelatii <strong>in</strong>tre nivelul <strong>de</strong> expre<strong>si</strong>e al diferitilor<br />
markerilor luati <strong>in</strong> studiu. Prelucrarea statistica a datelor stocate <strong>si</strong> arhivate - partial ;<br />
2) Studiul aspectelor celulare <strong>si</strong> moleculare ale procesului <strong>de</strong> apoptoza la nivelul celulelor leucemice (l<strong>in</strong>ii<br />
celulare <strong>si</strong> pacienti);<br />
Mo<strong>de</strong>le: -studiul viabilitatii <strong>si</strong> al apoptozei (la nivel membranar <strong>si</strong> la nivel mitocondrial) <strong>in</strong> celulele<br />
leucemice (l<strong>in</strong>ii celulare <strong>si</strong> celulele izolate d<strong>in</strong> sangele periferic al pacientilor diagnosticati cu<br />
LLC-B)<br />
-stabilirea unui mo<strong>de</strong>l celular <strong>in</strong> ve<strong>de</strong>rea <strong>de</strong>term<strong>in</strong>arii expre<strong>si</strong>ei prote<strong>in</strong>elor anti/pro<br />
apoptotice <strong>in</strong> celule <strong>de</strong> cultura <strong>si</strong> probe <strong>de</strong> sange prelevat <strong>de</strong> la pacientii diagnosticati cu LLC-B<br />
3) Studiul modificarilor celulare <strong>si</strong> moleculare priv<strong>in</strong>d nivelurile <strong>de</strong> expre<strong>si</strong>e ale biomarkerilor la nivelul<br />
celulelor leucemice<br />
Mo<strong>de</strong>le: -stabilirea unui mo<strong>de</strong>l celular <strong>si</strong> molecular pentru verificarea nivelului <strong>de</strong> expre<strong>si</strong>e a ZAP-70 <strong>si</strong><br />
CD23<br />
- stabilirea unui mo<strong>de</strong>l celular <strong>si</strong> molecular pentru verificarea nivelului <strong>de</strong> expre<strong>si</strong>e al Hsp70,<br />
Hsp90<br />
-<strong>in</strong>vestigare aprofundata la nivel molecular <strong>si</strong> celular a raspunsurilor biomarkerilor luati <strong>in</strong><br />
studiu la nivelul celulelor leucemice prelevate <strong>de</strong> la pacientii diagnosticati cu LLC-B la<br />
tratamentul cu AC
Disem<strong>in</strong>ari:<br />
Articole sub tipar-<strong>in</strong> lucru:<br />
1) The lymphocyte Immunophenotypical pattern <strong>in</strong> Chronic Lymphocytic Leukemia associated with hepatitis viral <strong>in</strong>fection<br />
Horia Bumbea, Ana-Maria Vladareanu, Anamaria V<strong>in</strong>tilescu, S<strong>in</strong>ziana Ra<strong>de</strong><strong>si</strong>, , Crist<strong>in</strong>a Ciufu, M<strong>in</strong>odora Onisai, Crist<strong>in</strong>a<br />
Baluta, Madal<strong>in</strong>a Begu, Camelia Dobrea, Victoria Arama, Adrian Stre<strong>in</strong>u- Cercel, , Sor<strong>in</strong> Arama, Alexandru Rafila<br />
2) Analy<strong>si</strong>s of geniste<strong>in</strong>-<strong>in</strong>duced apopto<strong>si</strong>s <strong>in</strong> human B-cell chronic leukemia, D. Hotnog, Ana-Maria Iova, Horia Bumbea,<br />
Christian Billard, Viviana Roman- <strong>in</strong> curs <strong>de</strong> redactare<br />
Carti : Spices and herbs <strong>in</strong> cancer prevention- V. Roman-contract cu Ed. Spr<strong>in</strong>ger- <strong>in</strong> curs <strong>de</strong> redactare<br />
Comunicari<br />
1) MITOCHONDRIAL APOPTOTIC MOLECULES AND GENISTEIN D.Hotnog, V. Roman, 21st Meet<strong>in</strong>g of the<br />
European Association of Cancer Research, 26-29 June, 2010,Oslo, Norway.<br />
2) EFFECTS OF GENISTEIN ON CELL GROWTH AND CELL CYCLE PROGRESSION IN B CELL CRHONIC<br />
LYMPHOCYTIC LEUKEMIA , D. Hotnog, V. Roman 14th International Congress of Immunology 22-27 August,<br />
2010, Kobe, Japan<br />
3) ANALIZA FAZELOR CICLULUI CELULAR SI A CRESTERII CELULARE CA URMARE A TRATAMENTULUI<br />
CU GENISTEINA UTILIZAND LINIA CELULARA EHEB” D. Hotnog, V. Roman Immunology and Cl<strong>in</strong>ical<br />
Allergology Jo<strong>in</strong>t Meet<strong>in</strong>g, 28 April-1 May, 2010, Sibiu, Romania<br />
4) POTENTIAL BIOLOGICAL MARKERS IN CHRONIC LYMPHOPROLIFERATIVE DISEASE, V. Roman, D.<br />
Hotnog, H.Bumbea, S.Ra<strong>de</strong><strong>si</strong>, BD Balkan Flow Users Meet<strong>in</strong>g Rov<strong>in</strong>j,31 mai-2 iunie 2010 Croatia<br />
5) POTENTIAL BIOLOGICAL MARKERS IN CHRONIC LYMPHOPROLIFERATIVE DISEASE, Viviana Roman, Dan<br />
Hotnog, Sanziana Ra<strong>de</strong><strong>si</strong>, Horia Bumbea,<br />
“Stefan S. Nicolau”, Bucuresti<br />
Medic<strong>in</strong>a Moleculara-Generatia urmatoare, 22-23 sept 2010, Institutul<br />
6) ANALIZA STATUSULUI MUTATIEI IGVH PRIN BIOLOGIE MOLECULAR IN LLC, Viviana Roman, Workshop<br />
Grupul <strong>de</strong> Diagnostic Hematologic Integrat Grupul <strong>de</strong> <strong>in</strong>itiativa <strong>in</strong> diagnosticul LLCA XIX-a CONFERINTA NATIONALA<br />
DE HEMATOLOGIE CLINICA SI TRANSFUZIONALA CU PARTICIPARE INTERNATIONALA 28-31 octombrie 2010<br />
7) ANALIZA RETROSPECTIVA A CAZURILOR CU SUSPICIUNEA DE SINDROM LIMFOPROLIFERATIV<br />
CRONIC – ANALIZA REZULTATELOR IMUNOFENOTIPICE PE O PERIOADA DE 12 LUNI Horia Bumbea,<br />
Oana Cazaceanu, Ana-Maria Vladareanu, Anamaria V<strong>in</strong>tilescu, Madal<strong>in</strong>a Begu, Crist<strong>in</strong>a Baluta, Mihaela Gaman,<br />
M<strong>in</strong>odora Onisai, Anca Nicolescu, Viola Popov ,Bucuresti, Romania AL VI-lea Congres National <strong>de</strong> Citometrie 6-8 mai<br />
2010 Eforie N
Disem<strong>in</strong>ari (II):<br />
8) DIAGNOSTICUL LYMPHOMA/LEUKEMIA BURKITT -PREZENTARE DE CAZ DIAGNOSIS OF BURKITT<br />
LYMPHOMA/LEUKEMIA – CASE REPORT Anamaria V<strong>in</strong>tilescu, Horia Bumbea, Oana Cazaceanu, Ana-Maria<br />
Vladareanu, Madal<strong>in</strong>a Begu, Crist<strong>in</strong>a Baluta, Dana Va<strong>si</strong>le, Mihaela Gaman, M<strong>in</strong>odora Onisai, Lav<strong>in</strong>ia Barsan, Crist<strong>in</strong>a<br />
Mar<strong>in</strong>escu Bucuresti, Romania AL VI-lea Congres National <strong>de</strong> Citometrie 6-8 mai 2010 Eforie N<br />
9) DIAGNOSTICUL LYMOHOPMA/LEUKEMIA BURKITT-PREZENTARE DE CAZ Anamaria V<strong>in</strong>tilescu (Iova), AM<br />
Vlãdãreanu, H.Bumbea, M. Begu, C. Bãluþã, O Cãzãceanu, D.Va<strong>si</strong>le, L. Barsan, M. Onisai CONGRESUL ANUAL AL<br />
ASOCIATIEI MEDICALE ROMÂNE 6 - 8 mai 2010<br />
10) VIRAL INFECTIOUS IN CHRONIC LYMPHOPROLIFERATIVE DISORDERS - IMMUNOPHENOTYPIC<br />
CHANGES Horia Bumbea, , S<strong>in</strong>ziana Ra<strong>de</strong><strong>si</strong> ,Ana-Maria Vladareanu, Anamaria V<strong>in</strong>tilescu, Viviana Roman, , Dan<br />
Hotnog , Victoria Arama ,Crist<strong>in</strong>a Ciufu, Crist<strong>in</strong>a Baluta, , Oana Cazaceanu , Andreea Ichim, Ir<strong>in</strong>a Voican, Diana<br />
Cisleanu, Mihaela Gaman,, Crist<strong>in</strong>a Mar<strong>in</strong>escu, Anca Nicolescu, M<strong>in</strong>odora Onisai,Sor<strong>in</strong> Arama, BD Balkan Flow Users<br />
Meet<strong>in</strong>g Rov<strong>in</strong>j,31 mai-2 iunie 2010 Croatia<br />
11) VIRAL INFECTIOUS IN CHRONIC LYMPHOPROLIFERATIVE DISORDERS - IMMUNOPHENOTYPIC<br />
CHANGES Horia Bumbea, Ana-Maria Vladareanu, S<strong>in</strong>ziana Ra<strong>de</strong><strong>si</strong>, Anamaria V<strong>in</strong>tilescu, Viviana Roman, Crist<strong>in</strong>a Ciufu,<br />
Dan Hotnog, Victoria Arama, M<strong>in</strong>odora Onisai, MV Popov, Crist<strong>in</strong>a Baluta, Oana Cazaceanu, Andreea Ichim, Ir<strong>in</strong>a<br />
Voican, Diana Cisleanu, Crist<strong>in</strong>a Mar<strong>in</strong>escu, Sor<strong>in</strong> Arama, A Rafila, A Stre<strong>in</strong>u-Cercel, Anca Nicolescu, Mihaela Gaman,<br />
A. Ichim, M. Begu EHA 2010 Barcelona, 10-13 June 2010, 14th Congress of the European Hematology Society.<br />
12) ANALIZA RETROSPECTIVA A REZULATELOR DIAGNOSTICULUI IMUNOFENOTIPIC IN<br />
LIMFOPROLIFERARILE CRONICE. Horia Bumbea-UMF Bucuresti SUUB, Cl<strong>in</strong>ica Hematologie, Workshop Grupul <strong>de</strong><br />
Diagnostic Hematologic Integrat Grupul <strong>de</strong> <strong>in</strong>itiativa <strong>in</strong> diagnosticul llca xix-a confer<strong>in</strong>ta nationala <strong>de</strong> hematologie<br />
cl<strong>in</strong>ica <strong>si</strong> transfuzionala cu participare <strong>in</strong>ternationala 28-31 octombrie 2010<br />
Evenimente organizate<br />
MASA ROTUNDA cu tema ,, Actualitati <strong>si</strong> perspective <strong>in</strong> limfoproliferarile cornice-translatia datelor sti<strong>in</strong>tifice <strong>in</strong> practica<br />
cl<strong>in</strong>ica’’, organizata <strong>de</strong> Cl<strong>in</strong>ica Hematologie Spitalul Univer<strong>si</strong>tar <strong>de</strong> Urgenta Bucuresti, <strong>in</strong> data <strong>de</strong> 11 Decembrie 2010, ce<br />
cupr<strong>in</strong><strong>de</strong> <strong>in</strong> program prezentari d<strong>in</strong> tema Proiectului <strong>de</strong> Cercetare BAC-LC<br />
1. Leucemia Limfatica Cronica-<strong>de</strong> la teorie la practica, obiect al cercetarii fundamentale <strong>si</strong> cl<strong>in</strong>ice-activitatea Grupului <strong>de</strong><br />
<strong>in</strong>itiative <strong>in</strong> diagnosticul LLC- Sef lucr. Dr Horia Bumbea<br />
2. Rezultatele analizei imunofenotipice <strong>de</strong> confirmare a diagnosticului <strong>de</strong> leucemie limfocitara cronica –program <strong>de</strong>rulat <strong>in</strong><br />
perioada 2009-2010- Dr Anamaria V<strong>in</strong>tilescu, Sef lucr. Dr Horia Bumbea, Dr Sanziana Ra<strong>de</strong><strong>si</strong>, Prof Dr Ana-Maria<br />
Vladareanu<br />
3. <strong>Biomarkeri</strong> <strong>in</strong> limfoproliferarile cornice-raprort <strong>in</strong>termediary al <strong>de</strong>sfasurarii proiectului BAC-LC-Dr Viviana Roman
Activitatile prevazute a se realiza <strong>in</strong> anul 2011<br />
Etapa 4<br />
Studiul modularii expre<strong>si</strong>ei biomarkerilor luati <strong>in</strong> studiu <strong>in</strong>a<strong>in</strong>te <strong>si</strong> dupa tratarea cu<br />
AC <strong>si</strong> implicatii ale <strong>agenti</strong>lor <strong>de</strong> <strong>chimiopreventie</strong> <strong>in</strong> ciclul celular<br />
1) Determ<strong>in</strong>area nivelului <strong>de</strong> expre<strong>si</strong>e <strong>si</strong> a ARNm corespunzator pentru CD38 CD20, <strong>in</strong>ante <strong>si</strong> dupa<br />
tratarea cu AC<br />
2) Determ<strong>in</strong>area nivelului <strong>de</strong> expre<strong>si</strong>e <strong>si</strong> a ARNm corespunzator pentru prote<strong>in</strong>ele<br />
pro/antiapoptotice <strong>in</strong>ante <strong>si</strong> dupa tratarea cu AC<br />
3) Determ<strong>in</strong>area prezentei sCD23 <strong>in</strong> seruri recoltate <strong>de</strong> la pacientii diagnosticati cu LLC-B<br />
4) Determ<strong>in</strong>area activitatii telomerazice <strong>in</strong>a<strong>in</strong>te <strong>si</strong> dupa tratarea cu AC<br />
5) Corelatii <strong>in</strong>tre activitatea telomerazica <strong>si</strong> ciclu celular<br />
6) Determ<strong>in</strong>area nivelului <strong>de</strong> expre<strong>si</strong>e a cicl<strong>in</strong>elor D1, D2, <strong>in</strong>a<strong>in</strong>te <strong>si</strong> dupa traterea cu AC.<br />
7) Determ<strong>in</strong>area nivelurilor <strong>de</strong> expre<strong>si</strong>e ale <strong>in</strong>hibitorilor ciclului celular <strong>in</strong>ante <strong>si</strong> dupa tratarea cu AC<br />
8) Corelatii <strong>in</strong>tre nivelul <strong>de</strong> expre<strong>si</strong>e al diferitilor markerilor luati <strong>in</strong> studiu. Prelucrarea statistica a<br />
datelor stocate <strong>si</strong> arhivate d<strong>in</strong> fazele anterioare<br />
9) Stabilirea unui set m<strong>in</strong>im <strong>de</strong> biomarkeri care raspund <strong>in</strong> acela<strong>si</strong> mod la modularea pr<strong>in</strong> AC <strong>in</strong><br />
LLC.<br />
10) Corelarea tipurilor patologice luate <strong>in</strong> studiu <strong>si</strong> datelor provenite d<strong>in</strong> laboratorul precl<strong>in</strong>ic cu<br />
datele experimentale rezultate <strong>in</strong> urma tratamentelor. Interperetarea <strong>si</strong> evaluarea studiului<br />
realizat.
Obiectivele <strong>si</strong> rezultatele preconizate a se obt<strong>in</strong>e; elementele <strong>de</strong><br />
orig<strong>in</strong>alitate ment<strong>in</strong>ute<br />
Obiective <strong>si</strong> rezultate<br />
1. Acumularea <strong>de</strong> noi cunosti<strong>in</strong>te priv<strong>in</strong>d actiunea <strong>agenti</strong>lor <strong>de</strong> <strong>chimiopreventie</strong> <strong>si</strong> o mai buna<br />
<strong>in</strong>telegere a mecanismelor bazale ale biomarkerilor ca urmare a cercetarilor efectuate<br />
2. Introducerea <strong>in</strong> practica curenta <strong>de</strong> diagnostic a rezultatelor obt<strong>in</strong>ute <strong>in</strong> cadru proiectului avand<br />
<strong>in</strong> ve<strong>de</strong>re ca o paleta <strong>de</strong> biomarkeri specifici utilizati <strong>in</strong> <strong>de</strong>term<strong>in</strong>area diagnosticului poate<br />
conduce la un tratament cat mai a<strong>de</strong>cvat, chiar personalizat<br />
3. Corelatiile-partiale-obt<strong>in</strong>ute pana acum ne <strong>in</strong>dreptatesc sa cre<strong>de</strong>m ca cercetarile ulterioare vor<br />
aduce un plus <strong>de</strong> <strong>in</strong>formatie <strong>si</strong> ca vom fi capabili, sa efectuam un diagnostic <strong>si</strong> un tratament <strong>in</strong><br />
conformitate cu standar<strong>de</strong>le d<strong>in</strong> ELN-ERIC asa cum o fac <strong>si</strong> alte laboratoare d<strong>in</strong> aceasta retea<br />
4. Detectarea mutatiilor d<strong>in</strong> IgVh ne va oferii po<strong>si</strong>bilitatea <strong>de</strong> a fi trecuti <strong>in</strong> lista laboratoarelor care<br />
efectueaza acest tip <strong>de</strong> analiza (<strong>si</strong> acest tip <strong>de</strong> corelatii <strong>in</strong>tre biomarkeri) d<strong>in</strong> cadrul ELN-ERIC<br />
5. Promovarea rezultatele relevante <strong>si</strong> <strong>in</strong> alte tipuri <strong>de</strong> cancer pentru a obt<strong>in</strong>e strategii pentru<br />
viitoarele trialuri cl<strong>in</strong>ice, avand ca scop o <strong>chimiopreventie</strong> <strong>si</strong>gura <strong>si</strong> eficienta
Estimarea necesarului <strong>de</strong> f<strong>in</strong>antare pentrul ultimul an<br />
Cu toate ca nu au fost a<strong>si</strong>gurate <strong>de</strong>cat o parte d<strong>in</strong> fondurile contractate (aprox. 13% <strong>in</strong> 2009 <strong>si</strong><br />
aprox. 24% <strong>in</strong> 2010) proiectul a cont<strong>in</strong>uat <strong>in</strong> limita fondurilor disponibilizate.<br />
Asa cum am mentionat <strong>si</strong> <strong>in</strong> cererile referitoare la suplimentare <strong>de</strong> fonduri (septembrie 2009,<br />
aprilie 2010), pr<strong>in</strong> eforturi personale conjugate, atat ale mele cat <strong>si</strong> ale colegului meu, Dr. Horia Bumbea am<br />
reu<strong>si</strong>t sa fim acceptati, nu numai <strong>in</strong> cadrul retelei europene <strong>de</strong> leucemie (European LeukemiaNet) ci <strong>si</strong> <strong>in</strong> cadrul<br />
European Research Initiative on CLL (ERIC)- WP 7, <strong>de</strong>dicat leucemiei cronice limfocitare-CLL. ERIC reprez<strong>in</strong>ta<br />
rezultatul asocierii unui numar con<strong>si</strong><strong>de</strong>rabil <strong>de</strong> cercetatori (atat d<strong>in</strong> ELN cat <strong>si</strong> d<strong>in</strong> SWG- scientific work<strong>in</strong>g group<br />
al EHA-European Hematology Association) implicati <strong>in</strong> cercetarea cl<strong>in</strong>ica d<strong>in</strong> diferite tari europene (Franta,<br />
Germania, Marea Britanie, Grecia, Italia, Spania, Suedia), fi<strong>in</strong>d <strong>de</strong>ci o onoare pentru noi ca am fost acceptati <strong>in</strong><br />
cadrul organizatiei mai sus referite.<br />
Acceptarea <strong>in</strong> cadrul acesteia s-a facut pe baza rezultatelor activitatii noastre anterioare <strong>de</strong><br />
cercetare <strong>si</strong> a proiectului PN II nr.62-078/2008 priv<strong>in</strong>d studiul aprofundat al unei game ext<strong>in</strong>se <strong>de</strong> biomarkeri<br />
d<strong>in</strong> limfoproliferarile cronice, corelatiile d<strong>in</strong>tre acestia <strong>si</strong> implicatiile ulterioare priv<strong>in</strong>d diagnosticul <strong>si</strong> cursul bolii.<br />
Grupul ERIC are drept scop standardizarea meto<strong>de</strong>lor pentru mai multi biomarkeri cu caracter <strong>de</strong> prognostic <strong>in</strong><br />
limfoproliferarile cronice <strong>in</strong> ve<strong>de</strong>rea stratificarii pacientilor <strong>in</strong> trailurile cl<strong>in</strong>ice. In ve<strong>de</strong>rea acestui lucru, pentru<br />
laboratoarele d<strong>in</strong> statele membre se ofera sprij<strong>in</strong> logistic necesar pentru <strong>in</strong><strong>de</strong>pl<strong>in</strong>irea acestui obiectiv. In aceasta<br />
conjunctura am <strong>in</strong>ceput <strong>de</strong>ja colaborarea cu Dr. Kostas Stamatopoulos priv<strong>in</strong>d standardizarea <strong>in</strong> Romania a<br />
meto<strong>de</strong>i <strong>de</strong> <strong>de</strong>term<strong>in</strong>are a statusului mutational al IgVh la pacientii cu limfoproliferari cronice, Centrul <strong>de</strong><br />
Imunologie - Institultul “Stefan S. Nicolau” Bucuresti <strong>si</strong> Centrul <strong>de</strong> Hematologie-Spitalului Univer<strong>si</strong>tar Bucuresti<br />
fi<strong>in</strong>d <strong>si</strong>ngurele unitati <strong>de</strong> cercetare d<strong>in</strong> tara care vor realiza aceasta analiza.<br />
Pentru ca activitatile pe plan national sa fie complementare <strong>si</strong> <strong>in</strong> <strong>si</strong>nergie cu cele <strong>de</strong>rulate pe plan<br />
european, supun atentiei dumneavoastra rugam<strong>in</strong>tea <strong>de</strong> a ment<strong>in</strong>e bugetul proiectului nostru PN II<br />
nr.62-078/2008 macar la nivelul contractat <strong>in</strong> anul 2008 pentru anul 2011 astfel <strong>in</strong>cat nivelul <strong>de</strong><br />
f<strong>in</strong>antare sa ne permita o buna <strong>de</strong>sfasurare a activitatilor la nivel european, <strong>in</strong> ve<strong>de</strong>rea cont<strong>in</strong>uarii muncii<br />
noastre, evitand pier<strong>de</strong>rea <strong>in</strong>formatiilor <strong>si</strong> a unor tehnici utile pe care le putem obt<strong>in</strong>e <strong>de</strong> la partenerii europeni<br />
fara costuri suplimentare pe plan national. Ceea ce solicitam este un sprij<strong>in</strong> real pentru eficientizarea activitatii<br />
<strong>de</strong> cercetare <strong>in</strong> Romania
Scrisori <strong>de</strong> sust<strong>in</strong>ere<br />
Accept publicare